PCT WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 7 : A61K 39/395, 38/17, 38/19 // C07K 16/28, 14/715

A1

(11) International Publication Number: **WO 00/21558**

(43) International Publication Date: 20 April 2000 (20.04.00)

(21) International Application Number: PCT/US99/23477

(22) International Filing Date: 8 October 1999 (08.10.99)

(30) Priority Data:
60/103,662 9 October 1998 (09.10.98) US

(71) Applicant *(for all designated States except US)*: BIOGEN, INC. [US/US]; 14 Cambridge Center, Cambridge, MA 02142 (US).

(72) Inventors; and
(75) Inventors/Applicants *(for US only)*: BROWNING, Jeff [US/US]; 32 Milton Road, Brookine, MA 02146 (US). PUGLIELLI, Maryann [US/US]; Apartment W, 3273 Flowers Road South, Atlanta, GA 30341 (US). AHMED, Rafi [US/US]; 1811 Durand Mill Drive, Atlanta, GA 30307 (US).

(74) Agent: FLYNN, Kerry, A.; Biogen, Inc., 14 Cambridge Center, Cambridge, MA 02142 (US).

(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published
With international search report.
Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.

(54) Title: REVERSAL OF VIRAL-INDUCED SYSTEMIC SHOCK AND RESPIRATORY DISTRESS BY BLOCKADE OF THE LYMPHOTOXIN BETA PATHWAY

(57) Abstract

This invention provides methods of inducing an antiviral response in an individual comprising administering to the individual an effective amount of a LT-B blocking agent and a pharmaceutically acceptable carrier. In particular this invention provides methods for treating viral-induced systemic shock and respiratory distress.